CN1315860A - 用于治疗人热潮红的方法 - Google Patents

用于治疗人热潮红的方法 Download PDF

Info

Publication number
CN1315860A
CN1315860A CN99810370A CN99810370A CN1315860A CN 1315860 A CN1315860 A CN 1315860A CN 99810370 A CN99810370 A CN 99810370A CN 99810370 A CN99810370 A CN 99810370A CN 1315860 A CN1315860 A CN 1315860A
Authority
CN
China
Prior art keywords
alkyl
glycopyrronium bromide
human
hydroxy
analog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN99810370A
Other languages
English (en)
Chinese (zh)
Inventor
阿瑟·M·布勃罗夫
杰弗里·D·于尔曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/184,512 external-priority patent/US5962505A/en
Application filed by Individual filed Critical Individual
Publication of CN1315860A publication Critical patent/CN1315860A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
CN99810370A 1998-08-31 1999-08-31 用于治疗人热潮红的方法 Pending CN1315860A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US9862998P 1998-08-31 1998-08-31
US60/098,629 1998-08-31
US09/184,512 1998-11-02
US09/184,512 US5962505A (en) 1998-08-31 1998-11-02 Method for treating hot flashes in humans
US09/360,074 1999-07-23
US09/360,074 US6395757B1 (en) 1998-08-31 1999-07-23 Method for treating hot flashes in humans

Publications (1)

Publication Number Publication Date
CN1315860A true CN1315860A (zh) 2001-10-03

Family

ID=27378636

Family Applications (1)

Application Number Title Priority Date Filing Date
CN99810370A Pending CN1315860A (zh) 1998-08-31 1999-08-31 用于治疗人热潮红的方法

Country Status (7)

Country Link
US (1) US6395757B1 (https=)
EP (1) EP1123098A4 (https=)
JP (1) JP4601170B2 (https=)
CN (1) CN1315860A (https=)
AU (1) AU762126B2 (https=)
CA (1) CA2339996C (https=)
WO (1) WO2000012087A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10136404A1 (de) * 2001-07-26 2003-02-20 Johannes Wohlrab Arzneiformulierung zur topischen Anwendung für die Therapie und Prophylaxe von Hyperhidrosis
US20050288343A1 (en) * 2004-05-19 2005-12-29 Andrew Rusowicz Process of preparing substituted carbamates and intermediates thereof
EP1861361A1 (en) * 2005-03-24 2007-12-05 Sosei R&D Ltd. Glycopyrronium salts and their therapeutic use
US20080260823A1 (en) * 2007-04-20 2008-10-23 Sciele Pharma, Inc. Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea
US8053004B2 (en) * 2007-10-08 2011-11-08 Starmaker Products, Llc Ointment for topical treatment of hot flashes and method of use
WO2013185024A1 (en) 2012-06-08 2013-12-12 The Ohio State University Treating burn and scar injury using tocotrienol
EP3473615B1 (en) 2013-02-28 2022-01-19 Journey Medical Corporation Glycopyrrolate salts
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
WO2015028976A2 (en) * 2013-08-30 2015-03-05 Mahesh Kandula Compounds and methods for the treatment of inflammatory diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
US3943242A (en) 1974-04-10 1976-03-09 American Cyanamid Company Deodorant composition containing a quaternary ammonium saccharinate salt
US4096254A (en) 1976-05-10 1978-06-20 Richardson-Merrell Inc. Method of treating the symptoms of menopause and osteoporosis
US5008111A (en) 1984-10-11 1991-04-16 Schering Corporation Physiological means of enhancing transdermal delivery of drugs
US4824676A (en) * 1984-10-11 1989-04-25 Schering Corporation Physiological means of enhancing transdermal delivery of drugs
KR930009787B1 (ko) * 1984-10-11 1993-10-11 케이 파마큐티칼스 약제의 경피성 도출계 및 그의 제조방법
US5155045A (en) 1985-01-25 1992-10-13 Trustees Of The University Of Penn. Use of male essence to alter female endocrine response
US5223528A (en) 1986-03-17 1993-06-29 University Of Florida Anticholinergic compounds, composititons and methods of treatment
US5258388A (en) 1986-03-17 1993-11-02 University Of Florida Anticholinergic compounds, compositions and methods of treatment
US5462950A (en) 1993-12-21 1995-10-31 Eli Lilly And Company Methods of treating menstrual symptoms and compositions therefore
US5512555A (en) 1994-07-21 1996-04-30 Merck & Co., Inc. Method of treating sweat-related conditions using finasteride, epristeride and a cholestan-3-one
US5525347A (en) 1995-01-31 1996-06-11 Medical University Of South Carolina Composition and methods for treating performance anxiety
US5744463A (en) 1996-06-03 1998-04-28 Bair; Glenn O. Treatment of side effects of progestins and progesterone analogues used for birth control
US5962505A (en) * 1998-08-31 1999-10-05 Bobrove; Arthur M. Method for treating hot flashes in humans

Also Published As

Publication number Publication date
JP2002523458A (ja) 2002-07-30
CA2339996C (en) 2009-06-16
WO2000012087A1 (en) 2000-03-09
CA2339996A1 (en) 2000-03-09
JP4601170B2 (ja) 2010-12-22
AU5903199A (en) 2000-03-21
EP1123098A4 (en) 2002-01-02
US6395757B1 (en) 2002-05-28
AU762126B2 (en) 2003-06-19
EP1123098A1 (en) 2001-08-16

Similar Documents

Publication Publication Date Title
JP5001651B2 (ja) うつ病の治療のためのロチゴチンの使用
RU2557533C2 (ru) Способы лечения синдрома фибромиалгии
AU775642B2 (en) Bupropion metabolites and methods of their synthesis and use
CN1068200C (zh) 9-顺-视黄酸及其盐和酯的药物用途
JP7781768B2 (ja) 神経学的および精神障害の治療方法
CN1214634A (zh) 止痒药物
JP2003529563A (ja) ビュープロピオン代謝産物並びにその合成および使用方法
CN1108097A (zh) 抑制皮肤和阴道萎缩的方法
CN1108255A (zh) 抑制经期前综合征/晚黄体期焦虑疾病的症状的方法
CN1832734A (zh) 用于治疗抑郁症的取代的2－氨基1,2,3,4－四氢化萘
CN1108654A (zh) 治疗月经症状的方法及组合物
CN1315860A (zh) 用于治疗人热潮红的方法
CN1107706A (zh) 抑制皮脂溢和痤疮的方法
CN1738611A (zh) 用作抗偏头痛剂的α－氨基酰胺衍生物
US20070053976A1 (en) Novel combination of drugs as antidepressant
CN1407890A (zh) 牛皮癣的治疗
US20100160295A1 (en) Treatment of restless leg syndrome and sleep disorders
ES2260910T3 (es) Metodos y composiciones que utilizan metabolitos de terfenadina en combinacion con inhibidores de leucotrienos.
CN1842328A (zh) 可用作抗炎剂的α－氨基酰胺衍生物
CN1809359A (zh) 用于治疗抑郁症和/或焦虑症的包含帕罗西汀和2－(s) －(4－氟－2－甲基－苯基)－哌嗪－1－羧酸[1－(r) －(3, 5－二－三氟－2－甲基-苯基) －乙基]甲基酰胺的联合药物
JPH023626A (ja) リシルオキシダーゼの抑制剤
CN1107703A (zh) 抑制女性多毛症和脱发的方法
EP1942891B1 (en) Novel combination of drugs as antidepressant
CN1100932A (zh) 用于治疗牛皮癣药的制备的取代的氮杂螺烷
EP0851856A1 (fr) Derives d'indole comme analogues melatonergiques

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication